No Results Found
The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.
Pfizer’s Infliximab, Sandoz’s Natalizumab & Samsung Bioepis’ Ustekinumab on Australia’s PBAC March 2025 Agenda
On 28 November 2024, Australia’s Pharmaceutical Benefits Scheme (PBS) published its agenda for the March 2025 Pharmaceutical Benefits Advisory Committee (PBAC) meeting. This follows the PBAC’s publication of its September 2024 intracycle meeting outcomes, which noted...